ArisGlobal Releases New Version of Its Unified Electronic Data Capture System
agCapture 3.2 Delivers on the Promise of Real Unification of Data Management Processes
ArisGlobal, a leading provider of solutions to the life sciences industry, has announced the immediate availability of agCapture™ 3.2, the newest release of ArisGlobal’s innovative EDC (Electronic Data Capture) system, fully unified with ePRO (electronic Patient Reported Outcome) RTSM (Randomization and Trial Supply Management), IWRS (Interactive Web Response System) and medical coding, and seamlessly integrated with CTMS (Clinical Trial Management System). agCapture is offered either as an on-premise or cloud solution.
“Trial sponsors are constantly searching for ways to reduce study costs and improve efficiencies while adhering to compliance requirements,” stated Simon Sparkes, executive vice president, ArisGlobal. “agCapture is simply a stand-out EDC system that is not only unified with our advanced ePro, RTSM and IWRS solutions, but is now fully integrated with CTMS using CDISC ODM (Clinical Data Interchange Standards Consortium Operational Data Model) standards as the basis of the integration. There is quite simply no other clinical drug development platform to match the ArisGlobal eClinical solution suite.”
agCapture 3.2 delivers many key features and enhancements that ensure a successful clinical study:
- Greater flexibility and adaptability: While agCapture can support paper studies, study teams can now also easily create hybrid studies that combine both manual double data entry (DDE) and EDC. Sites can be specified as an EDC site or a traditional paper as required.
- Staging areas: Streamlines the study design process by supporting different design phases, making it easier to validate changes and manage the change control process even after a study is live.
- Advanced study builder: Users can easily create studies using standard CRF templates, optimizing the study setup time, design and validation process. This provides real benefits such as reducing study build time, standardizing the study design, achieving full data consolidation instantly and eliminating training.
- EDC to CTMS integration: Relevant status data is automatically transmitted from a company’s EDC system to their CTMS, triggering key activities such as investigator payments and monitoring visits. The transfer of data such as trial, visit, subject and CRF statuses, along with subject-specific identifiers is exchanged between the two modules using the CDISC- ODM standards.
- SAML-enabled solution: agCapture is also now a SAML-enabled (Security Assertion Markup Language) solution that supports single- sign-on, providing simplified access to data across multiple applications.
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
